Apollon Raises $3.8M for Needle-Free Glucose Monitoring

Apollon, a South Korean innovator in non-invasive continuous glucose monitoring (CGM) technology, has successfully closed a $3.8 million Series A funding round. This significant capital injection is set to accelerate the development and validation of its groundbreaking needle-free device, which utilizes Raman spectroscopy to measure glucose levels directly on the skin's surface. The round was spearheaded by SBI Investment, with substantial participation from strategic investors including Naver, a tech giant preparing to launch its own digital healthcare division, and Daewoong, Apollon's established domestic distribution partner. Additional backing came from the Korea Credit Guarantee Fund and Mirae Holdings, bringing Apollon's total cumulative funding, including R&D grants, to over $7.6 million.

The core of Apollon's innovation lies in its proprietary technology that isolates glucose-specific wavelength signals, eschewing the need for invasive sensors. This advanced approach has enabled the creation of a remarkably compact device, roughly half the size of a smartphone, while maintaining high sensitivity. The company's commitment to rigorous scientific validation is underscored by its joint clinical research with MIT’s Laser Biomedical Research Center, with findings published in esteemed journals like the Journal of Diabetes Science and Technology. Furthermore, Apollon has built a robust intellectual property portfolio, filing 54 patents and securing 21 registrations, including 17 in the United States, establishing a formidable barrier to entry in the competitive biosensor market.

With this new funding, Apollon plans to conduct a crucial patient-focused clinical feasibility study at the renowned Joslin Diabetes Center, an affiliate of Harvard Medical School. This study will broaden the validation scope to include a diverse patient population, a key step in advancing its U.S. Food and Drug Administration (FDA) De Novo pathway strategy. The company has also received support from the Massachusetts eHealth Institute (MeHI), which will contribute to clinical trial expenses, highlighting the growing recognition of Apollon's potential.

The company's strategic expansion into the U.S. market is already underway, marked by the establishment of a U.S. entity in Boston in 2023 and successful participation in the MassChallenge accelerator program. Apollon has also bolstered its advisory board with prominent figures, including Medha Munshi, a Harvard Medical School professor and director at Joslin Diabetes Center, and Laurence Alberts, an experienced entrepreneur in the diabetes device sector. Collaborations with industry leaders such as Analog Devices and Oura further signal Apollon's intent to integrate its technology within the broader health tech ecosystem.

Aram Hong, CEO of Apollon, emphasized the strategic importance of their U.S. validation efforts, stating, "We first built validation in the United States through clinical trials, patents, and partnerships, and that work led to domestic investment." He added that upon completion of the Joslin trial and FDA pre-submission discussions, the company anticipates a significant re-evaluation in the U.S. market. Hong also expressed confidence in Korea's biomedical talent pool, suggesting that the most competitive non-invasive CGM commercialization technologies will emerge from the region.

The continuous glucose monitoring market is experiencing substantial growth, driven by increasing diabetes prevalence globally and a growing demand for less invasive and more convenient monitoring solutions. Projections indicate the global CGM market could reach tens of billions of dollars in the coming years. Apollon's needle-free approach directly addresses a key pain point for millions of individuals managing diabetes, positioning it to capture a significant share of this expanding market. The successful Series A funding, particularly with strategic investors like Naver, signals strong market confidence in Apollon's technological prowess and commercial potential.